NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

The price rise is in spite of, not because of the fact that NWBO had to shut up about Direct for almost a year.

And the price rise only happened now because of the recent Direct release.

Without that release, we'd likely linger in the high $7.00 to high $8.00 range.

Since NWBO has high powered investors like Woodford and given that all of the big milestones are much closer, NWBO knows that releasing information on Direct is no longer necessary to support the share price.

NWBO's position in 2015 is much stronger than it was in 2014 and it will only get better in 2016.

Remember, in a year's time we will almost certainly have the following information:

1. Whether HE in Germany is a feel-good designation with little meaning or a real financial factor for he company.

2. The results for DCVax L Phase 3

3. Whether we've made real progress on EAMS in the UK or not

These three things are individually at least as important as any single intermediate Direct Phase 2 data release and added together, they are much more important.